190 related articles for article (PubMed ID: 25909885)
1. Pharmacological targeting of guanosine monophosphate synthase suppresses melanoma cell invasion and tumorigenicity.
Bianchi-Smiraglia A; Wawrzyniak JA; Bagati A; Marvin EK; Ackroyd J; Moparthy S; Bshara W; Fink EE; Foley CE; Morozevich GE; Berman AE; Shewach DS; Nikiforov MA
Cell Death Differ; 2015 Nov; 22(11):1858-64. PubMed ID: 25909885
[TBL] [Abstract][Full Text] [Related]
2. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.
Zhuang D; Mannava S; Grachtchouk V; Tang WH; Patil S; Wawrzyniak JA; Berman AE; Giordano TJ; Prochownik EV; Soengas MS; Nikiforov MA
Oncogene; 2008 Nov; 27(52):6623-34. PubMed ID: 18679422
[TBL] [Abstract][Full Text] [Related]
3. A purine nucleotide biosynthesis enzyme guanosine monophosphate reductase is a suppressor of melanoma invasion.
Wawrzyniak JA; Bianchi-Smiraglia A; Bshara W; Mannava S; Ackroyd J; Bagati A; Omilian AR; Im M; Fedtsova N; Miecznikowski JC; Moparthy KC; Zucker SN; Zhu Q; Kozlova NI; Berman AE; Hoek KS; Gudkov AV; Shewach DS; Morrison CD; Nikiforov MA
Cell Rep; 2013 Oct; 5(2):493-507. PubMed ID: 24139804
[TBL] [Abstract][Full Text] [Related]
4. GMP synthase is essential for viability and infectivity of Trypanosoma brucei despite a redundant purine salvage pathway.
Li Q; Leija C; Rijo-Ferreira F; Chen J; Cestari I; Stuart K; Tu BP; Phillips MA
Mol Microbiol; 2015 Sep; 97(5):1006-20. PubMed ID: 26043892
[TBL] [Abstract][Full Text] [Related]
5. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
[TBL] [Abstract][Full Text] [Related]
6. Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools.
Bianchi-Smiraglia A; Bagati A; Fink EE; Moparthy S; Wawrzyniak JA; Marvin EK; Battaglia S; Jowdy P; Kolesnikova M; Foley CE; Berman AE; Kozlova NI; Lipchick BC; Paul-Rosner LM; Bshara W; Ackroyd JJ; Shewach DS; Nikiforov MA
Oncogene; 2017 Jan; 36(1):84-96. PubMed ID: 27181209
[TBL] [Abstract][Full Text] [Related]
7. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
[TBL] [Abstract][Full Text] [Related]
8. Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAF
Jandova J; Park SL; Corenblum MJ; Madhavan L; Snell JA; Rounds L; Wondrak GT
Mol Carcinog; 2022 Jun; 61(6):603-614. PubMed ID: 35417045
[TBL] [Abstract][Full Text] [Related]
9. Role of phosphodiesterase 2 in growth and invasion of human malignant melanoma cells.
Hiramoto K; Murata T; Shimizu K; Morita H; Inui M; Manganiello VC; Tagawa T; Arai N
Cell Signal; 2014 Sep; 26(9):1807-17. PubMed ID: 24705027
[TBL] [Abstract][Full Text] [Related]
10. Guanosine monophosphate synthase upregulation mediates cervical cancer progression by inhibiting the apoptosis of cervical cancer cells via the Stat3/P53 pathway.
Wang J; Wu Y; Li Y; Wang Y; Shen F; Zhou J; Chen Y
Int J Oncol; 2021 Apr; 58(4):. PubMed ID: 33649833
[TBL] [Abstract][Full Text] [Related]
11. Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma.
Yue L; Huang ZM; Fong S; Leong S; Jakowatz JG; Charruyer-Reinwald A; Wei M; Ghadially R
Melanoma Res; 2015 Apr; 25(2):138-48. PubMed ID: 25643237
[TBL] [Abstract][Full Text] [Related]
12. COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
Botti G; Fratangelo F; Cerrone M; Liguori G; Cantile M; Anniciello AM; Scala S; D'Alterio C; Trimarco C; Ianaro A; Cirino G; Caracò C; Colombino M; Palmieri G; Pepe S; Ascierto PA; Sabbatino F; Scognamiglio G
J Transl Med; 2017 Feb; 15(1):46. PubMed ID: 28231855
[TBL] [Abstract][Full Text] [Related]
13. IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma.
Carson CC; Moschos SJ; Edmiston SN; Darr DB; Nikolaishvili-Feinberg N; Groben PA; Zhou X; Kuan PF; Pandey S; Chan KT; Jordan JL; Hao H; Frank JS; Hopkinson DA; Gibbs DC; Alldredge VD; Parrish E; Hanna SC; Berkowitz P; Rubenstein DS; Miller CR; Bear JE; Ollila DW; Sharpless NE; Conway K; Thomas NE
Clin Cancer Res; 2015 May; 21(9):2167-76. PubMed ID: 25934889
[TBL] [Abstract][Full Text] [Related]
14. Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma.
Kumar R; Njauw CN; Reddy BY; Ji Z; Rajadurai A; Klebanov N; Tsao H
Oncogene; 2019 May; 38(18):3504-3520. PubMed ID: 30651601
[TBL] [Abstract][Full Text] [Related]
15. Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity.
Kaji T; Yamasaki O; Takata M; Otsuka M; Hamada T; Morizane S; Asagoe K; Yanai H; Hirai Y; Umemura H; Iwatsuki K
J Dermatol Sci; 2017 Jan; 85(1):51-57. PubMed ID: 27771229
[TBL] [Abstract][Full Text] [Related]
16. MERTK receptor tyrosine kinase is a therapeutic target in melanoma.
Schlegel J; Sambade MJ; Sather S; Moschos SJ; Tan AC; Winges A; DeRyckere D; Carson CC; Trembath DG; Tentler JJ; Eckhardt SG; Kuan PF; Hamilton RL; Duncan LM; Miller CR; Nikolaishvili-Feinberg N; Midkiff BR; Liu J; Zhang W; Yang C; Wang X; Frye SV; Earp HS; Shields JM; Graham DK
J Clin Invest; 2013 May; 123(5):2257-67. PubMed ID: 23585477
[TBL] [Abstract][Full Text] [Related]
17. N2-hydroxyguanosine 5'-monophosphate is a time-dependent inhibitor of Escherichia coli guanosine monophosphate synthetase.
Deras ML; Chittur SV; Davisson VJ
Biochemistry; 1999 Jan; 38(1):303-10. PubMed ID: 9890911
[TBL] [Abstract][Full Text] [Related]
18. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAF
Jandova J; Wondrak GT
J Invest Dermatol; 2022 May; 142(5):1456-1465.e1. PubMed ID: 34687745
[TBL] [Abstract][Full Text] [Related]
20. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas.
Lee JT; Li L; Brafford PA; van den Eijnden M; Halloran MB; Sproesser K; Haass NK; Smalley KS; Tsai J; Bollag G; Herlyn M
Pigment Cell Melanoma Res; 2010 Dec; 23(6):820-7. PubMed ID: 20973932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
